Developer docs
API playgroundTry for free, no card

Search company profiles

The Dion Foundation

Full company profile

uuid02icbif

Namestring
The Dion Foundation
Legal namestring
The Dion Foundation for Children with Rare Diseases, Inc.
Websiteurl
thedionfund.org
Company typeenum
Private
Founded yearint
2023
Descriptiontext

The Dion Foundation for Children with Rare Diseases is a Massachusetts-incorporated 501(c)(3) nonprofit (Federal Tax ID: 92-2280592) founded in 2023 by Joe and Courtney Dion after their two children were diagnosed with Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5), an ultra-rare, progressive pediatric neuromuscular disease affecting an estimated 2,000 people across the US and Europe. The foundation's core mission is funding the first-ever US clinical trial of a disease-modifying gene therapy for LGMD2C through a flagship partnership with Atamyo Therapeutics, to which it has committed over $1,000,000 in community-raised capital to deploy the first US clinical trial site at the Powell Gene Therapy Center, University of Florida. It does not develop the therapy itself; the funded asset, ATA-200, is an adeno-associated virus (AAV) gene therapy carrying the human SGCG transgene, administered as a single intravenous infusion at a dose of 1.0E+14 vg/kg in children aged 6 to 13.

The foundation's commercial model is community-driven donation fundraising layered with event-based experiential revenue and merchandise. It operates a digital donation storefront at thedionfund.org supporting one-time, weekly, monthly, quarterly, and annual gifts at preset tiers from $25 to $1,000 plus custom amounts, a branded merchandise store with items priced from $15 to $55, and a portfolio of annual events including a charity golf tournament with corporate sponsorships up to $5,000, a 5K run/walk, Boston and Chicago Marathon charity teams with $10,000-per-runner minimums, a casino cruise, and a Discovery Channel partnership via co-founder Joe Dion on 'Harpoon Hunters'. Distribution is primarily direct-to-consumer through the foundation's own e-commerce site plus the GiveGain and FlipCause platforms.

The foundation serves three identifiable stakeholder groups: affected LGMD2C patient families (currently anchored by three partner families: the Dions, Baileys, and Colellas, encompassing six named pediatric patients), individual and corporate donors and volunteers, and the broader rare disease advocacy community engaged through MassBio, BIO, and STAT News channels for legislative work on the Rare Pediatric Disease Priority Review Voucher Program and the Give Kids a Chance Act. It also runs a HIPAA-compliant patient registry and a Patient Community Board launching in 2026. The organization is governed by a Board of Directors and a small team led by Co-Founders Joe and Courtney Dion, with a Fundraising Chair and Fundraising and Creative Director driving execution. As of March 2026, four patients had been dosed with ATA-200 with no serious adverse events and greater than 90% muscle fiber expression of the SGCG protein observed at six-month biopsy.

Short descriptiontext

The Dion Foundation is a 501(c)(3) nonprofit founded in 2023 that funds gene therapy research and clinical trials for children with LGMD2C, a rare pediatric muscular dystrophy. It raises community donations, operates fundraising events, and co-funds the first US ATA-200 gene therapy trial through Atamyo Therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, nonprofit charitable foundation, gene therapy trials, patient advocacy services, community fundraising events
Industry3 codes
PRIMARYBPAGACAM
Rare Disease & Special Needs Support Organizations
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking Foundations813211
SIC code1 code
  • Services-Social Services8300
Product category
Rare Disease Research Funding and Patient Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Fundraising
TypeOthers
Description

The foundation raises funds through individual donations (one-time, weekly, monthly, quarterly, annual), corporate sponsorships for events, and fundraising events including golf tournaments, 5K runs, marathon teams, casino cruises, and other community events. Every dollar is allocated to research, clinical trials, and operational costs of the nonprofit.

thedionfund.org
2Merchandise Sales
TypeHardware Sales
Description

The foundation operates an online store selling branded merchandise including t-shirts, hoodies, hats, and beanies. Items range from $15 to $55. Revenue from merchandise sales supports the foundation's mission and clinical trial funding.

thedionfund.org
Marketing channels16 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details3 tiers
1One-Time, Weekly, Monthly, Quarterly, Annual Donation Tiers
ModelSubscriptionBilling cadenceMonthly
Notes

Preset donation tiers of $25, $50, $100, $250, $500, $1,000 plus custom amount. Donors can select one-time or recurring (weekly, monthly, quarterly, annual) donation frequencies.

thedionfund.org
2Merchandise Store Items
ModelUnit PricingBilling cadencePay-as-you-go
Notes

T-shirts from $15-$30, hoodies $40-$55, hats $20-$30, crews $40-$45. Items include adult and youth sizes.

thedionfund.org
3Golf Tournament Sponsorship Levels
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Condor Sponsor $5,000 (18 holes for foursome, lunch, dinner banquet, logo on all materials); Albatross Sponsor $2,500 (whiskey tasting table); Eagle Sponsor $1,000 (single golf hole sponsorship); Birdie Sponsor $500 (shared hole sponsorship).

thedionfund.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

The Dion Foundation is a 501(c)(3) nonprofit that raises and deploys charitable funds to finance the first-in-human clinical trial of ATA-200 gene therapy for Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5), while operating a global patient and family community and producing fundraising events. Revenue is generated through individual donations (one-time and recurring), corporate event sponsorships, and branded merchandise sales, with proceeds directed toward Atamyo Therapeutics' gene therapy program, rare disease advocacy, and family support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% of muscle fibers expressing the SGCG protein in treated patients, demonstrating effective gene delivery (90.2% for patient 1 and 92.1% for patient 2 at 6-month biopsy).
+3 more records
Product overview1 text field

The Dion Foundation is a 501(c)(3) non-profit charitable organization established in 2023 to fund research and find treatments for Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5). The organization operates as a unified charitable platform offering donation-based fundraising for clinical trials, a patient and family community with registry services, branded merchandise sales, and experiential fundraising events (golf tournaments, 5K runs, marathon teams). The core focus is financing the first-ever clinical trial for LGMD2C gene therapy through Atamyo Therapeutics' ATA-200 program.

Product and service9 records
1Charitable Donations and Fundraising Platform
CategoryFundraising
Description

Online donation platform accepting one-time and recurring gifts at preset and custom amounts, channeling funds to LGMD2C clinical trials and family programs. Tax-deductible under 501(c)(3) status.

2Clinical Trial Funding Partnership with Atamyo Therapeutics (ATA-200)
CategoryClinical Research Funding
Description

Co-funding program that financed the US deployment of Atamyo Therapeutics' Phase 1b/2 trial of ATA-200 AAV gene therapy for LGMD2C/R5 at the Powell Gene Therapy Center, University of Florida, with over $1,000,000 of foundation-raised capital committed.

3LGMD2C Patient and Family Community
CategoryPatient Community
Description

Global patient community for families affected by LGMD2C providing private Facebook forums, peer connection, advocacy, and pathways to clinical trial participation.

4Branded Merchandise Store
CategoryMerchandise
Description

E-commerce store selling t-shirts ($15-$30), hoodies ($40-$55), hats ($20-$30), and accessories (including the 'No Child Left Behind' apparel and 'Harpoon Rare Disease' collection), with revenue directed to foundation programs.

5Par for a Cure Charity Golf Tournament
CategoryFundraising Event
Description

Annual charity golf tournament at Marshfield Country Club, MA with corporate sponsorship tiers ranging from Birdie ($500) to Condor ($5,000), offering branding, foursome inclusion, and event access.

6Hustle for the Muscle 5K
CategoryFundraising Event
Description

Annual 5K run/walk charity event held in Waltham, MA and Naples, FL, with team registration, individual fundraising pages, and vendor/sponsor booths to support LGMD research.

7Boston Marathon Team Dion
CategoryFundraising Event
Description

Charity running team for the Boston Marathon requiring a $10,000 per-runner fundraising minimum, managed via GiveGain, with proceeds supporting LGMD2C clinical trials.

8LGMD2C Patient Registry
CategoryPatient Registry
Description

HIPAA-compliant patient registry recruiting LGMD2C/R5 patients to assist researchers with clinical study identification, natural history study participation, advocacy, and care network connections.

9Educational and Awareness Materials
CategoryEducational Resources
Description

Downloadable fundraising flyers, brochures, and sponsorship information for community distribution and LGMD awareness building.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-07
Description

The Dion Foundation has partnered with LGMD Awareness Foundation as part of a Foundation Spotlight to raise awareness for limb-girdle muscular dystrophy. The LGMD Awareness Foundation provides resources, events, and campaigns to support individuals living with LGMD.

2The Bailey Family
Strategic tierModerateTypeOthersAnnounced on2025-09-07
Description

The Bailey Family (Brian and Chrissy Bailey with children Kennedy and Berkeley, both diagnosed with LGMD2C in summer 2025) joined The Dion Foundation as partner families in September 2025 to help raise awareness, accelerate funding for research, and support children living with LGMD2C.

thedionfund.org
3The Colella Family
Strategic tierModerateTypeOthersAnnounced on2025-09-07
Description

The Colella Family (Grant, Alexa, Ryan, and Charlotte Colella, diagnosed with LGMD2C) joined The Dion Foundation as partner families in September 2025 to help fundraise, advocate, and shine a light on children living with LGMD2C.

thedionfund.org
Strategic tierModerateTypeGTM or Marketing PartnerAnnounced on2024-10-27
Description

The Dion Foundation participated in the MassBio Patient Advocacy Summit 2024 and the 2025 State of Possible Conference, connecting with the life sciences industry in Massachusetts. Joe and Courtney Dion served as panel speakers discussing their journey from parent advocates to clinical trial funders alongside Atamyo Therapeutics.

Strategic tierModerateTypeGTM or Marketing PartnerAnnounced on2024-10-27
Description

The Dion Foundation participated in the 2024 BIO Patient & Health Advocacy Summit in Washington, D.C., where Joe and Courtney Dion shared their family story and the importance of the Pediatric Priority Review Voucher. The foundation also appeared on the I AM BIO podcast discussing rare disease hope and advocacy.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-04
Description

The Dion Foundation partnered with Atamyo Therapeutics to finance and support the expansion of the US clinical trial of ATA-200 gene therapy for LGMD2C/R5. The foundation provided over $1,000,000 in financial support to deploy the first US clinical trial site at the Powell Gene Therapy Center, University of Florida. The partnership was expanded in February 2026 to support financing of the ongoing Phase 1b/2 dose-escalation study evaluating the safety and efficacy of ATA-200 in children with LGMD-R5.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-04
Description

Genethon is a non-profit research organization and pioneer in developing gene therapies for rare diseases. Atamyo Therapeutics is a spin-off of Genethon. ATA-200 gene therapy is based on the research of Isabelle Richard, Ph.D., Research Director at CNRS in France and head of the Progressive Muscular Dystrophies Laboratory at Genethon. The Dion Foundation's partnership with Atamyo connects the foundation to Genethon's 30+ years of gene therapy development expertise.

8Powell Gene Therapy Center at University of Florida
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-02
Description

The Powell Gene Therapy Center at the University of Florida, led by Dr. Barry Byrne (Associate Chair of Pediatrics and Director), is the site where the first US patients were dosed with ATA-200 gene therapy. Dr. Barry Byrne serves as the principal investigator of the Phase 1b/2 clinical trial (NCT05973630). The Dion Foundation's funding enabled the deployment of this US clinical site.

thedionfund.org
Strategic tierCoreTypeGTM or Marketing Partner
Description

The MDA Conference serves as a platform where Atamyo Therapeutics and The Dion Foundation present clinical trial results for ATA-200 gene therapy. MDA is a leading organization in neuromuscular disease research and care. The foundation's partnership with Atamyo was announced at MDA Conference 2026 where promising results were presented.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specifically named as a Dion Foundation partner; both organizations focus on limb-girdle muscular dystrophy patient education, awareness events, and resource provision, with overlapping patient and family communities.

TypeDirect peer
Description

Patient-founded nonprofit targeting facioscapulohumeral muscular dystrophy (FSHD), another LGMD-adjacent muscular dystrophy subtype; comparable as a small, parent-led research and advocacy funder in the muscular dystrophy space.

TypeBroad incumbent
Description

Large incumbent across all neuromuscular diseases; runs the MDA Conference where ATA-200 data is presented and partners with the foundation on awareness, but operates at much greater scale and across multiple indications.

TypeBroad incumbent
Description

Rare-disease advocacy and patient community platform with similar awareness, fundraising, and policy work; comparable as a cross-disease peer but at a broader scale and without the single-trial funding focus.

TypeDirect peer
Description

Patient-founded nonprofit funding Duchenne muscular dystrophy gene therapy and translational research; uses a similar model of community fundraising, venture-style diligence on academic and industry programs, and partnership co-funding.

TypeDirect peer
Description

Family-launched nonprofit funding translational research and clinical trials for Duchenne muscular dystrophy; another small-team, family-driven model that directs donations to specific drug-development programs in ultra-rare pediatric disease.

TypeBroad incumbent
Description

Umbrella advocacy organization for rare diseases including LGMD subtypes; comparable at the policy and patient-advocacy layer (PPRV, Give Kids a Chance Act) rather than as a single-disease funder.

TypeDirect peer
Description

Advocacy and research-funding nonprofit for Duchenne muscular dystrophy, with deep advocacy on FDA pathways (similar PPRV exposure) and a long track record of co-funding DMD gene-therapy trials — a close functional analog to The Dion Foundation for LGMD2C.

TypeDirect peer
Description

Parent-driven nonprofit that has become a primary funder of Angelman syndrome gene-therapy programs, channeling community donations directly to biotech and academic programs — a structural twin of the Dion Foundation model.

TypeDirect peer
Description

Family-founded nonprofit that funded early SMA drug development (Spinraza, Zolgensma) and continues to fund gene-therapy trials. Highly comparable as a parent-driven rare pediatric neuromuscular disease foundation channeling community-raised capital into clinical-stage therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Dion Foundation

Rare Disease Research Funding and Patient Advocacythedionfund.org

The Dion Foundation is a 501(c)(3) nonprofit founded in 2023 that funds gene therapy research and clinical trials for children with LGMD2C, a rare pediatric muscular dystrophy. It raises community donations, operates fundraising events, and co-funds the first US ATA-200 gene therapy trial through Atamyo Therapeutics.

What The Dion Foundation does

The Dion Foundation for Children with Rare Diseases is a Massachusetts-incorporated 501(c)(3) nonprofit (Federal Tax ID: 92-2280592) founded in 2023 by Joe and Courtney Dion after their two children were diagnosed with Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5), an ultra-rare, progressive pediatric neuromuscular disease affecting an estimated 2,000 people across the US and Europe. The foundation's core mission is funding the first-ever US clinical trial of a disease-modifying gene therapy for LGMD2C through a flagship partnership with Atamyo Therapeutics, to which it has committed over $1,000,000 in community-raised capital to deploy the first US clinical trial site at the Powell Gene Therapy Center, University of Florida. It does not develop the therapy itself; the funded asset, ATA-200, is an adeno-associated virus (AAV) gene therapy carrying the human SGCG transgene, administered as a single intravenous infusion at a dose of 1.0E+14 vg/kg in children aged 6 to 13.

The foundation's commercial model is community-driven donation fundraising layered with event-based experiential revenue and merchandise. It operates a digital donation storefront at thedionfund.org supporting one-time, weekly, monthly, quarterly, and annual gifts at preset tiers from $25 to $1,000 plus custom amounts, a branded merchandise store with items priced from $15 to $55, and a portfolio of annual events including a charity golf tournament with corporate sponsorships up to $5,000, a 5K run/walk, Boston and Chicago Marathon charity teams with $10,000-per-runner minimums, a casino cruise, and a Discovery Channel partnership via co-founder Joe Dion on 'Harpoon Hunters'. Distribution is primarily direct-to-consumer through the foundation's own e-commerce site plus the GiveGain and FlipCause platforms.

The foundation serves three identifiable stakeholder groups: affected LGMD2C patient families (currently anchored by three partner families: the Dions, Baileys, and Colellas, encompassing six named pediatric patients), individual and corporate donors and volunteers, and the broader rare disease advocacy community engaged through MassBio, BIO, and STAT News channels for legislative work on the Rare Pediatric Disease Priority Review Voucher Program and the Give Kids a Chance Act. It also runs a HIPAA-compliant patient registry and a Patient Community Board launching in 2026. The organization is governed by a Board of Directors and a small team led by Co-Founders Joe and Courtney Dion, with a Fundraising Chair and Fundraising and Creative Director driving execution. As of March 2026, four patients had been dosed with ATA-200 with no serious adverse events and greater than 90% muscle fiber expression of the SGCG protein observed at six-month biopsy.

The Dion Foundation firmographics

Firmographics
Name
The Dion Foundation
Legal name
The Dion Foundation for Children with Rare Diseases, Inc.
Website
https://thedionfund.org
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
The Dion Foundation is a 501(c)(3) nonprofit founded in 2023 that funds gene therapy research and clinical trials for children with LGMD2C, a rare pediatric muscular dystrophy. It raises community donations, operates fundraising events, and co-funds the first US ATA-200 gene therapy trial through Atamyo Therapeutics.
Ownership category
akta.pro rank

The Dion Foundation industry classification

Industry
Product category
Rare Disease Research Funding and Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking Foundations (813211)
SIC
Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGACAM
Rare Disease & Special Needs Support Organizations
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds

Keywords

  • Rare disease research
  • Nonprofit charitable foundation
  • Gene therapy trials
  • Patient advocacy services
  • Community fundraising events

Where The Dion Foundation is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

The Dion Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Donations and Fundraising: The foundation raises funds through individual donations (one-time, weekly, monthly, quarterly, annual), corporate sponsorships for events, and fundraising events including golf tournaments, 5K runs, marathon teams, casino cruises, and other community events. Every dollar is allocated to research, clinical trials, and operational costs of the nonprofit.
  2. Merchandise Sales: The foundation operates an online store selling branded merchandise including t-shirts, hoodies, hats, and beanies. Items range from $15 to $55. Revenue from merchandise sales supports the foundation's mission and clinical trial funding.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyOne-Time, Weekly, Monthly, Quarterly, Annual Donation Tiers
Unit PricingPay-as-you-goMerchandise Store Items
One time/ perpetual licensePay-as-you-goGolf Tournament Sponsorship Levels

Go-to-market motion1 record

Distribution channels8 records

Marketing channels16 records

The Dion Foundation product offering

Product offering

Core offering

The Dion Foundation is a 501(c)(3) nonprofit that raises and deploys charitable funds to finance the first-in-human clinical trial of ATA-200 gene therapy for Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5), while operating a global patient and family community and producing fundraising events. Revenue is generated through individual donations (one-time and recurring), corporate event sponsorships, and branded merchandise sales, with proceeds directed toward Atamyo Therapeutics' gene therapy program, rare disease advocacy, and family support.

Product overview

The Dion Foundation is a 501(c)(3) non-profit charitable organization established in 2023 to fund research and find treatments for Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5). The organization operates as a unified charitable platform offering donation-based fundraising for clinical trials, a patient and family community with registry services, branded merchandise sales, and experiential fundraising events (golf tournaments, 5K runs, marathon teams). The core focus is financing the first-ever clinical trial for LGMD2C gene therapy through Atamyo Therapeutics' ATA-200 program.

Differentiator

Problem solved

Functional benefit

Products and services

  • Charitable Donations and Fundraising Platform Online donation platform accepting one-time and recurring gifts at preset and custom amounts, channeling funds to LGMD2C clinical trials and family programs. Tax-deductible under 501(c)(3) status.
  • Clinical Trial Funding Partnership with Atamyo Therapeutics (ATA-200) Co-funding program that financed the US deployment of Atamyo Therapeutics' Phase 1b/2 trial of ATA-200 AAV gene therapy for LGMD2C/R5 at the Powell Gene Therapy Center, University of Florida, with over $1,000,000 of foundation-raised capital committed.
  • LGMD2C Patient and Family Community Global patient community for families affected by LGMD2C providing private Facebook forums, peer connection, advocacy, and pathways to clinical trial participation.
  • Branded Merchandise Store E-commerce store selling t-shirts ($15-$30), hoodies ($40-$55), hats ($20-$30), and accessories (including the 'No Child Left Behind' apparel and 'Harpoon Rare Disease' collection), with revenue directed to foundation programs.
  • Par for a Cure Charity Golf Tournament Annual charity golf tournament at Marshfield Country Club, MA with corporate sponsorship tiers ranging from Birdie ($500) to Condor ($5,000), offering branding, foursome inclusion, and event access.
  • Hustle for the Muscle 5K Annual 5K run/walk charity event held in Waltham, MA and Naples, FL, with team registration, individual fundraising pages, and vendor/sponsor booths to support LGMD research.
  • Boston Marathon Team Dion Charity running team for the Boston Marathon requiring a $10,000 per-runner fundraising minimum, managed via GiveGain, with proceeds supporting LGMD2C clinical trials.
  • LGMD2C Patient Registry HIPAA-compliant patient registry recruiting LGMD2C/R5 patients to assist researchers with clinical study identification, natural history study participation, advocacy, and care network connections.
  • Educational and Awareness Materials Downloadable fundraising flyers, brochures, and sponsorship information for community distribution and LGMD awareness building.

Quantifiable outcome

  • Over 90% of muscle fibers expressing the SGCG protein in treated patients, demonstrating effective gene delivery (90.2% for patient 1 and 92.1% for patient 2 at 6-month biopsy).
  • +3 more outcomes

Companies that use The Dion Foundation

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles4 records

The Dion Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

The Dion Foundation partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor, moderate, flagship and core.

  • LGMD Awareness FoundationminorGTM or Marketing Partner · 7 September 2025The Dion Foundation has partnered with LGMD Awareness Foundation as part of a Foundation Spotlight to raise awareness for limb-girdle muscular dystrophy. The LGMD Awareness Foundation provides resources, events, and campaigns to support individuals living with LGMD.
  • The Bailey FamilymoderateOthers · 7 September 2025The Bailey Family (Brian and Chrissy Bailey with children Kennedy and Berkeley, both diagnosed with LGMD2C in summer 2025) joined The Dion Foundation as partner families in September 2025 to help raise awareness, accelerate funding for research, and support children living with LGMD2C.
  • The Colella FamilymoderateOthers · 7 September 2025The Colella Family (Grant, Alexa, Ryan, and Charlotte Colella, diagnosed with LGMD2C) joined The Dion Foundation as partner families in September 2025 to help fundraise, advocate, and shine a light on children living with LGMD2C.
  • MassBiomoderateGTM or Marketing Partner · 27 October 2024The Dion Foundation participated in the MassBio Patient Advocacy Summit 2024 and the 2025 State of Possible Conference, connecting with the life sciences industry in Massachusetts. Joe and Courtney Dion served as panel speakers discussing their journey from parent advocates to clinical trial funders alongside Atamyo Therapeutics.
  • BIO (Biotechnology Innovation Organization)moderateGTM or Marketing Partner · 27 October 2024The Dion Foundation participated in the 2024 BIO Patient & Health Advocacy Summit in Washington, D.C., where Joe and Courtney Dion shared their family story and the importance of the Pediatric Priority Review Voucher. The foundation also appeared on the I AM BIO podcast discussing rare disease hope and advocacy.
  • Atamyo TherapeuticsflagshipStrategic or Co-development Partner · 4 September 2024The Dion Foundation partnered with Atamyo Therapeutics to finance and support the expansion of the US clinical trial of ATA-200 gene therapy for LGMD2C/R5. The foundation provided over $1,000,000 in financial support to deploy the first US clinical trial site at the Powell Gene Therapy Center, University of Florida. The partnership was expanded in February 2026 to support financing of the ongoing Phase 1b/2 dose-escalation study evaluating the safety and efficacy of ATA-200 in children with LGMD-R5.
  • GenethoncoreStrategic or Co-development Partner · 4 September 2024Genethon is a non-profit research organization and pioneer in developing gene therapies for rare diseases. Atamyo Therapeutics is a spin-off of Genethon. ATA-200 gene therapy is based on the research of Isabelle Richard, Ph.D., Research Director at CNRS in France and head of the Progressive Muscular Dystrophies Laboratory at Genethon. The Dion Foundation's partnership with Atamyo connects the foundation to Genethon's 30+ years of gene therapy development expertise.
  • Powell Gene Therapy Center at University of FloridacoreStrategic or Co-development Partner · 2 June 2024The Powell Gene Therapy Center at the University of Florida, led by Dr. Barry Byrne (Associate Chair of Pediatrics and Director), is the site where the first US patients were dosed with ATA-200 gene therapy. Dr. Barry Byrne serves as the principal investigator of the Phase 1b/2 clinical trial (NCT05973630). The Dion Foundation's funding enabled the deployment of this US clinical site.
  • Muscular Dystrophy Association (MDA)coreGTM or Marketing PartnerThe MDA Conference serves as a platform where Atamyo Therapeutics and The Dion Foundation present clinical trial results for ATA-200 gene therapy. MDA is a leading organization in neuromuscular disease research and care. The foundation's partnership with Atamyo was announced at MDA Conference 2026 where promising results were presented.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

The Dion Foundation competitors and assessment

Company assessment

Direct peers

  • LGMD Awareness Foundation: Specifically named as a Dion Foundation partner; both organizations focus on limb-girdle muscular dystrophy patient education, awareness events, and resource provision, with overlapping patient and family communities.
  • Solve FSHD: Patient-founded nonprofit targeting facioscapulohumeral muscular dystrophy (FSHD), another LGMD-adjacent muscular dystrophy subtype; comparable as a small, parent-led research and advocacy funder in the muscular dystrophy space.
  • CureDuchenne: Patient-founded nonprofit funding Duchenne muscular dystrophy gene therapy and translational research; uses a similar model of community fundraising, venture-style diligence on academic and industry programs, and partnership co-funding.
  • Charley's Fund: Family-launched nonprofit funding translational research and clinical trials for Duchenne muscular dystrophy; another small-team, family-driven model that directs donations to specific drug-development programs in ultra-rare pediatric disease.
  • Parent Project Muscular Dystrophy (PPMD): Advocacy and research-funding nonprofit for Duchenne muscular dystrophy, with deep advocacy on FDA pathways (similar PPRV exposure) and a long track record of co-funding DMD gene-therapy trials — a close functional analog to The Dion Foundation for LGMD2C.
  • Foundation for Angelman Syndrome Therapeutics (FAST): Parent-driven nonprofit that has become a primary funder of Angelman syndrome gene-therapy programs, channeling community donations directly to biotech and academic programs — a structural twin of the Dion Foundation model.
  • CureSMA: Family-founded nonprofit that funded early SMA drug development (Spinraza, Zolgensma) and continues to fund gene-therapy trials. Highly comparable as a parent-driven rare pediatric neuromuscular disease foundation channeling community-raised capital into clinical-stage therapeutics.

Broad incumbents

  • Muscular Dystrophy Association (MDA): Large incumbent across all neuromuscular diseases; runs the MDA Conference where ATA-200 data is presented and partners with the foundation on awareness, but operates at much greater scale and across multiple indications.
  • Global Genes: Rare-disease advocacy and patient community platform with similar awareness, fundraising, and policy work; comparable as a cross-disease peer but at a broader scale and without the single-trial funding focus.
  • National Organization for Rare Disorders (NORD): Umbrella advocacy organization for rare diseases including LGMD subtypes; comparable at the policy and patient-advocacy layer (PPRV, Give Kids a Chance Act) rather than as a single-disease funder.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

The Dion Foundation social profiles

Digital presence

The Dion Foundation compliance and trust

Trust signal

Compliance1 record

The Dion Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Dion Foundation leadership team

Management profile

Number of profiles

Profiles8 records

The Dion Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Dion Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Dion Foundation

What does The Dion Foundation do?

The Dion Foundation is a 501(c)(3) nonprofit that raises and deploys charitable funds to finance the first-in-human clinical trial of ATA-200 gene therapy for Limb-Girdle Muscular Dystrophy Type 2C (LGMD2C/R5), while operating a global patient and family community and producing fundraising events. Revenue is generated through individual donations (one-time and recurring), corporate event sponsorships, and branded merchandise sales, with proceeds directed toward Atamyo Therapeutics' gene therapy program, rare disease advocacy, and family support.

Is The Dion Foundation a public or private company?

The Dion Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The Dion Foundation founded?

The Dion Foundation was founded in 2023. It employs 1 to 10 people.

Where is The Dion Foundation based?

The Dion Foundation is headquartered in Boston, United States, in the North America region.

How does The Dion Foundation make money?

Two revenue lines are on record. Donations and Fundraising is the primary driver. The others are merchandise Sales.

Who are The Dion Foundation's main competitors?

Direct peers on record are LGMD Awareness Foundation, Solve FSHD, CureDuchenne, Charley's Fund, Parent Project Muscular Dystrophy (PPMD), Foundation for Angelman Syndrome Therapeutics (FAST) and CureSMA. Broad incumbents are Muscular Dystrophy Association (MDA), Global Genes and National Organization for Rare Disorders (NORD).

Does The Dion Foundation have an API?

No public API is recorded for The Dion Foundation.

What industry is The Dion Foundation in?

The Dion Foundation's product category is Rare Disease Research Funding and Patient Advocacy. Its primary akta.pro industry code is BPAGACAM, Rare Disease & Special Needs Support Organizations, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales